Alcántara MA

Language: Spanish
References: 6
Page: 247-250
PDF size: 210.43 Kb.

Text Extraction

No abstract,

REFERENCES

1. Alcántara-Montero A. Novedades en el tratamiento médico de la vejiga hiperactiva SEMERGEN-Medicina de Familia. 2016;42:557-65.

2. Yamaguchi O, Kakizaki H, Homma Y, Igawa Y, et al. Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a postmarketing, open-label study in Japan (MILAI study). BJU Int. 2015;116:612-22.

3. Abrams P, Kelleher C, Staskin D, Rechberger T, Kay R, Martina R, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, doubleblind, dose-ranging, phase 2 study(Symphony). Eur Urol. 2015;67:577-88.

4. de Greef-van der Sandt I, Newgreen D, Schaddelee M, Dorrepaal C, et al. A quantitative benefit-risk assessment approach to improve decision making in drug development: Application of a multicriteria decision analysis model in the development of combination therapy for overactive bladder. Clin Pharmacol Ther. 2016;99:442-51.

5. Drake MJ, Chapple C, Esen AA, Athanasiou S, Cambronero J, Mitcheson D, et al. Efficacy and Safety of Mirabegron Addon Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE). Eur Urol. 2016;70:136-45.

6. Herschorn S, Chapple CR, Abrams P, Arlandis S, Mitcheson D, Lee KS, et al. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU Int. 2017. doi: 10.1111/bju.13882.